At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 86 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Leronlimab (700mg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)
In Brief
A Phase 2 clinical trial evaluating Placebo and Leronlimab (700mg) for Coronavirus Disease 2019. Completed, enrolled 86 participants across 12 sites.
Detailed Summary
This is a Phase 2, two-arm, randomized, double blind, placebo controlled multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with mild-to-moderate symptoms of respiratory illness caused by coronavirus 2019 infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronavirus Disease 2019
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartApr 2020
First PostedApr 2020
Primary CompletionJul 2020
Study CompletionSep 2021
TodayJul 2026
First PostedApr 13, 2020
Enrollment StartApr 1, 2020
Primary CompletionJul 21, 2020
Study CompletionSep 20, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.2 years ago
Interventions
Placebodrug
Placebo
Leronlimab (700mg)drug
Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)